Drug Profile
Research programme: memantine reformulations - NeuroMolecular Pharmaceuticals
Alternative Names: Memantine reformulations - NeuroMolecularLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator NeuroMolecular Pharmaceuticals
- Class Amines; Analgesics; Antidementias; Antiglaucomas; Antiparkinsonians; Antispastics; Antitussives; Eye disorder therapies; Nitrates; Nootropics; Organic bridged compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported CNS disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in CNS-disorders in USA
- 21 Feb 2008 NeuroMolecular Pharmaceuticals is seeking partnership opportunities for this research programme (http://www.neuromolecular.com)